
Cellink AB acquires Ginolis Oy for €70m
Under the agreement, Cellink AB is set to acquire all shares for a purchase price on cash- and debt-free basis of €70m. Forty per cent of the...

Biomarker identifies high-risk COVID-19 patients
The findings of virologists headed by Elisabeth Puchhammer-Stöckl from the Medical University Vienna may pave the way to early identification of...

EMA recommends to continue AZD1222 vaccinations
After the stops of AstraZeneca's COVID-19 vaccine or specific batches of it in 13 EU member states, the EU regulatory authority EMA has analysed the...

B.1.1.7 variant associated with higher mortality
Previous reports from British autorities that suggested a 30 to 100% higher mortality of B.1.1.7 than of the previously dominant form in Europe are...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

Oxular Ltd raises US$37m
Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
The company's subsidiary C4X Discovery Ltd got €7m upfront with potential to gain €414m in total for the global commercialisation rights for its...